Evidence map›Paper›PMID 36546683›Full record

ArticleHistology and histopathology2023

LHPP promotes the intracellular reactive oxygen species accumulation and sensitivity of gastric cancer to cisplatin via JNK and p38 MAPK pathways.

Kai Gao, Ning Yin, Zhaolong Shen, Qiqing Li, Peng Chen, Kaiyan Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. LHPP expression in triple-negative breast cancer promotes tumor growth and metastasis by modulating the tumor microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Histidine Phosphorylation: Protein Kinases and Phosphatases.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kai GaoDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, PR China.
Ning YinDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, PR China.
Zhaolong ShenDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, PR China.
Qiqing LiDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, PR China.
Peng ChenDepartment of General Surgery, The Third Hospital of Zhuzhou, Zhuzhou, Hunan, PR China.
Kaiyan YangDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, PR China. kaiyan_yang@yeah.net.
Central South University · CNZhuzhou Central Hospital · CN

Funding

Natural Science Foundation of Hunan Province 2020JJ4857
6 · The paper itself

Abstract

backgroundCisplatin is the first-line chemotherapy drug for the treatment of gastric cancer (GC) patients. However, GC patients who are resistant to cisplatin often do not benefit from it. Therefore, finding a key molecule that affects cisplatin sensitivity is expected to enhance the efficacy of cisplatin in GC treatment.

methodsThe human GC cell lines SGC-7901 and BGC-823 were used. The protein chip array was used to screen the cisplatin-resistance genes from the complete response and non-complete response GC patients' tissues, then, the differential gene expression analysis, GO function annotation analysis, and KEGG pathway enrichment analysis were performed. The GC tissue chip in the GEO database was analyzed to screen the target gene. Flow cytometry, Hoechst 33342 staining assay, Western Blot, MTT, tumor sphere formation, cell cycle, and apoptosis assays were performed to explore the effect of Phospholysine Phosphohistidine Inorganic Pyrophosphate Phosphatase (LHPP) on the apoptosis, stemness, and reactive oxygen species (ROS) accumulation of cisplatin-resistant GC cells treated with cisplatin. In vivo, the cisplatin-resistant GC cell lines transfected with pcDNA-LHPP or si-LHPP were injected subcutaneously into mice to construct GC subcutaneous xenograft GC models.

resultsBased on protein chip array and bioinformatics analysis, it was found that LHPP is the core molecule in the cisplatin resistance regulatory network in GC, and its expression is down-regulated in GC cisplatin-resistant tissues and cells. In vitro and in vivo experimental results show that the up-regulated expression of LHPP is closely related to the increase in sensitivity of GC to cisplatin. Mechanically, we found that overexpression of LHPP may inhibit the activation of the JNK and p38 MAPK pathways, promote cisplatin-induced ROS accumulation, suppress stemness, and enhance the sensitivity of GC to cisplatin.

conclusionsUp-regulation of LHPP may inhibit the activation of the JNK and p38 MAPK pathways, attenuate stemness, and enhance the accumulation of intracellular ROS, thereby promoting cisplatin-mediated GC cell apoptosis and enhancing cisplatin sensitivity.

Indexed as

CisplatinStomach NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansInorganic PyrophosphataseMicep38 Mitogen-Activated Protein KinasesReactive Oxygen SpeciesSignal TransductionCisplatinInorganic Pyrophosphatasep38 Mitogen-Activated Protein Kinasesphospholysine phosphohistidine inorganic pyrophosphate phosphatase, humanReactive Oxygen Species

Identifiers

PMID36546683
OpenAlexW4312095656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.